欧盟授予RBD1016作为孤儿的药物地位,这是对严重肝炎德尔塔病毒的实验性SIRNA疗法,以加速其发展。 The EU granted orphan drug status to RBD1016, an experimental siRNA therapy for severe Hepatitis Delta Virus, to speed its development.

欧洲药品署已准许RBD1016为孤儿指定药品,这是对乙型肝炎德尔塔病毒(HDV)的一种实验性SIRNA疗法,这是一种严重的肝炎形式,影响到全世界数百万人,并造成迅速的肝脏损伤。 The European Medicines Agency has granted Orphan Drug Designation to RBD1016, an experimental siRNA therapy for Hepatitis Delta Virus (HDV), a severe form of hepatitis affecting millions worldwide and causing rapid liver damage. 由苏州Ribo生命科学和Ribocure制药公司利用GalNAc-siRNA平台开发,RBD1016针对关键的病毒因素,正在全球第二阶段试验中。 Developed by Suzhou Ribo Life Science and Ribocure Pharmaceuticals using a GalNAc-siRNA platform, RBD1016 targets key viral factors and is in global Phase II trials. 对稀有、威胁生命条件的治疗的指定,为加速发展提供了监管和商业利益。 The designation, given to treatments for rare, life-threatening conditions, offers regulatory and commercial benefits to accelerate development. 目前,HDV的治疗选择有限,治疗旨在解决未得到满足的重大医疗需求。 HDV currently has limited treatment options, and the therapy aims to address a significant unmet medical need.